MedTrace Logo

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

NCT01592617 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2015-08-13

No results posted yet for this study

Summary

The investigators identified three cancer-testis antigens, as targets for cancer vaccination against lung cancer. In this clinical study, the investigators examine using a combination of three peptides from these three antigens (S-488410) the safety, immunogenicity, and antitumor effect of vaccine treatment for advanced non-small cell lung cancer patients.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

S-488410

In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).

Sponsors & Collaborators

  • Showa University

    collaborator OTHER

  • Fukushima Medical University

    collaborator OTHER

  • Tohoku University

    collaborator OTHER

  • Shionogi

    collaborator INDUSTRY

  • Tokyo University

    collaborator OTHER

  • University of Chicago

    collaborator OTHER

  • Shiga University

    lead OTHER

Principal Investigators

  • Yataro Daigo, MD, PhD · Department of Medical Oncology, Shiga University of Medical Science

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-08-31
Completion
2015-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01592617 on ClinicalTrials.gov